Groowe Groowe / Newsroom / LGVN
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

LGVN News

Longeveron Inc. Common Stock

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

globenewswire.com
LLY NVO VKTX LGVN

Form 8-K

sec.gov
LGVN

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

prnewswire.com
VRTX OCGN LGVN LCTX

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

globenewswire.com
LGVNR LGVN

Form 8-K

sec.gov
LGVN

Form 8-K

sec.gov
LGVN

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

globenewswire.com
FBLG FATE MESO LGVN

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

prnewswire.com
MESO LGVN LCTX MNKD

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

globenewswire.com
LGVNR LGVN

Form 8-K

sec.gov
LGVN